OncoMatch/Clinical Trials/NCT05376111
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Is NCT05376111 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Venetoclax, Azacitidine for t-cell acute lymphoblastic leukemia.
Treatment: Venetoclax, Azacitidine — The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Patients who have received chemotherapy treatments related to the disease.
Lab requirements
Kidney function
serum creatinine > 1.5x ULN
Liver function
total bilirubin > 1.5x ULN, ALT/AST > 2.5x ULN or > 1.5x ULN with liver involvement
Cardiac function
No history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia, atrial fibrillation, II-degree heart block, myocardial infarction within one year, congestive heart failure, or symptomatic coronary heart disease requiring drug treatment
Liver dysfunction (total bilirubin > 1.5 times the upper limit of the normal range, ALT/AST > 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine > 1.5 times the upper limit of the normal value). Patients with a history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05376111 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages